<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711410967</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711410967</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group><article-title>Endothelial Nitric Oxide Synthase Gene Variants and Coronary Heart Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kolovou</surname>
<given-names>Genovefa</given-names>
</name>
<degrees>MD, PhD, FESC, SFASA, FACS</degrees>
<xref ref-type="aff" rid="aff1-0003319711410967">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711410967"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giannakopoulou</surname>
<given-names>Vasiliki</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711410967">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711410967"><label>1</label>1st Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece</aff>
<aff id="aff2-0003319711410967"><label>2</label>Thriasio Hospital, Cardiology Department, Elefsina, Greece</aff>
<author-notes>
<corresp id="corresp1-0003319711410967">Genovefa Kolovou, 1st Cardiology Department, Head of Lipid Clinic, Onassis Cardiac Surgery Center, Athens, Greece Email: <email>genovefa@kolovou.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>84</fpage>
<lpage>85</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Nitric oxide synthase (NOS) was first recognized<sup><xref ref-type="bibr" rid="bibr1-0003319711410967">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711410967">2</xref></sup> and reported in 1989. After that, considerable research was published (using the term “nitric oxide synthase,” a search of PubMed from its inception through March 2011 produced 54 335 articles). The significance of NO gained even more importance following the Nobel Prize award in 1998 to R. Furchgott, L. Ignarro, and F. Murad. In humans and generally in mammals, these synthases catalyze NO production from L-arginine and co-substrates, molecular oxygen, and 5 electrons provided by nicotinamide adenine dinucleotide phosphate (NADPH).<sup><xref ref-type="bibr" rid="bibr3-0003319711410967">3</xref></sup> There are 3 NOS isoforms that are products of different genes, with different localization, regulation, catalytic properties, and inhibitor sensitivity. NOS-1 is located mainly in neuronal tissue, NOS-2 is inducible in a wide range of cells and tissues, whereas NOS-3 is found in vascular endothelial cells (also called eNOS).<sup><xref ref-type="bibr" rid="bibr4-0003319711410967">4</xref></sup> However, NOS-3 is not only expressed by vascular endothelial cells (where it mediates relaxation, migration, and inhibition of vascular smooth muscle cells growth, inhibition of platelet and leukocyte adhesion to vascular endothelium, and limitation of the oxidation of low-density lipoprotein particles), but it is also present within cardiac myocytes, where the enzyme associates with the scaffolding/regulatory protein caveolin 3 in T tubules of plasmalemmal caveolae.<sup><xref ref-type="bibr" rid="bibr5-0003319711410967">5</xref></sup> It follows that many investigators have studied the cardiac effects of various NOS inhibitors, NO-donating drugs, and NO itself. Indeed we have witnessed an explosion of information regarding NO, leading to a better understanding of its physiological and pathophysiological roles.<sup><xref ref-type="bibr" rid="bibr6-0003319711410967">6</xref></sup>
</p>
<p>Another, important issue concerning NO was the encoding of the <italic>NOS-3</italic> gene, which has been extensively screened for polymorphisms. Much attention has focused on putatively functional variants (<italic>-786T&gt;C</italic> [rs2070744], <italic>intron 4</italic> 27-base-pair repeat, and <italic>Glu298Asp</italic> [rs1799983]). In this issue of <italic>Angiology</italic>, Rahimi and Nourosi-Rad<sup><xref ref-type="bibr" rid="bibr7-0003319711410967">7</xref></sup> reported the role of <italic>NOS-3</italic> G894T polymorphism on predisposition to coronary heart disease (CHD). They found significantly higher frequency of the <italic>NOS-3</italic> 894T allele in patients with CHD, independently of the presence of diabetes mellitus, compared with controls. They also observed 2.15 times increased CHD risk in the presence of the T allele of <italic>NOS-3</italic> gene.<sup><xref ref-type="bibr" rid="bibr7-0003319711410967">7</xref></sup> Studies examining the functionality of <italic>NOS-3</italic> G894T polymorphism found that individuals with the <italic>-786C</italic> variant have lower <italic>NOS-3</italic> messenger RNA (mRNA) and serum nitrite/nitrate levels.<sup><xref ref-type="bibr" rid="bibr8-0003319711410967">8</xref></sup> Also, homozygotes for the <italic>-786C</italic> allele have a decreased maximal forearm blood flow response to acetylcholine, a pharmacologic model to evaluate NO production in vivo.<sup><xref ref-type="bibr" rid="bibr9-0003319711410967">9</xref></sup> In case–control studies among Japanese participants, those carrying the C-786 and T894 alleles of the <italic>NOS-3</italic> gene had a significantly higher risk of vasospastic angina, supporting a functional role of these polymorphisms on coronary endothelial function.<sup><xref ref-type="bibr" rid="bibr10-0003319711410967">10</xref></sup> In addition, mice in which the <italic>NOS-3</italic> gene has been deleted are hypertensive, and those with deletions in both the apolipoprotein E and <italic>NOS-3</italic> genes have increased susceptibility to atherosclerosis.<sup><xref ref-type="bibr" rid="bibr11-0003319711410967">11</xref>,<xref ref-type="bibr" rid="bibr12-0003319711410967">12</xref></sup>
</p>
<p>Endothelial NO availability is influenced by intensity of synthesis. Thus, the gene encoding the NOS-3 is an attractive candidate gene for cardiovascular risk.<sup><xref ref-type="bibr" rid="bibr13-0003319711410967">13</xref></sup> A recently published meta-analysis supported an influence of this variant on CHD risk.<sup><xref ref-type="bibr" rid="bibr14-0003319711410967">14</xref></sup> Nevertheless, there are some conflicting studies that were discussed by Rahimi and Nourosi-Rad.<sup><xref ref-type="bibr" rid="bibr7-0003319711410967">7</xref></sup> One can argue that the small number of individuals in this study is a major limitation. However, research evaluating the genetic associations with atherosclerosis is a promising tool for primary and secondary prevention.<sup><xref ref-type="bibr" rid="bibr15-0003319711410967">15</xref></sup> The <italic>NOS-3</italic> G894T polymorphism may become a useful genetic marker to identify individuals prone to the development of atherosclerotic diseases.</p>
<p>CHD is a multifactorial disorder with genotype, environmental, and ethnic interactions, which have an important role in its development. Larger populations of patients and controls need to be evaluated before confirming the presence of genetic determinants of CHD<sup><xref ref-type="bibr" rid="bibr16-0003319711410967">16</xref></sup> such as polymorphisms of <italic>NOS-3</italic>.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711410967">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<fn-group>
<fn fn-type="financial-disclosure" id="fn2-0003319711410967">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711410967">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Ferrige</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Moncada</surname>
<given-names>S.</given-names>
</name>
</person-group> <article-title>Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor</article-title>. <source>Nature</source>. <year>1987</year>;<volume>327</volume>(<issue>6122</issue>):<fpage>524</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711410967">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuehr</surname>
<given-names>DJ.</given-names>
</name>
</person-group> <article-title>Structure-function aspects in the nitric oxide synthases</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>1997</year>;<volume>37</volume>:<fpage>339</fpage>–<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711410967">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alderton</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Knowles</surname>
<given-names>RG.</given-names>
</name>
</person-group> <article-title>Nitric oxide synthases: structure, function and inhibition</article-title>. <source>Biochem J</source>. <year>2001</year>;<volume>357</volume>(<issue>pt 3</issue>):<fpage>593</fpage>–<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711410967">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsden</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Heng</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Scherer</surname>
<given-names>SW</given-names>
</name><etal/></person-group>. <article-title>Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthetases gene</article-title>. <source>J Biol Chem</source>. <year>1993</year>;<volume>268</volume>(<issue>23</issue>):<fpage>17478</fpage>–<lpage>17488</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711410967">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feron</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Belhassen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kobzik</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Kelly</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Endothelial nitric oxide synthase targeting to caveolae: specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>(<issue>37</issue>):<fpage>22810</fpage>–<lpage>22814</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711410967">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lowenstein</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Michel</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Nitric oxide signaling comes of age: 20 years and thriving</article-title>. <source>Cardiovasc Res</source>. <year>2007</year>;<volume>75</volume>(<issue>2</issue>):<fpage>207</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711410967">
<label>7</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rahimi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Nourosi-Rad</surname>
<given-names>R.</given-names>
</name></person-group> <article-title>Association of Endothelial Nitric Oxide Synthase Gene Variant (G894T) with Coronary Artery Disease in Western Iran</article-title>. <source>Angiology</source>. <year>2011</year>. <comment>doi: 0003319711409741</comment>
</citation>
</ref>
<ref id="bibr8-0003319711410967">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>M</given-names>
</name><etal/></person-group>. <article-title>Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T→C mutation associated with coronary spastic angina</article-title>. <source>Hum Mol Genet</source>. <year>2000</year>;<volume>9</volume>(<issue>18</issue>):<fpage>2629</fpage>–<lpage>2637</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711410967">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rossi</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Taddei</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Virdis</surname>
<given-names>A</given-names>
</name><etal/></person-group>. <article-title>The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>41</volume>(<issue>6</issue>):<fpage>938</fpage>–<lpage>945</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711410967">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yasue</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>M</given-names>
</name><etal/></person-group>. <article-title>T-786–&gt;C mutation in the 5’-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>99</volume>(<issue>22</issue>):<fpage>2864</fpage>–<lpage>2870</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711410967">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuhlencordt</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Gyurko</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>F</given-names>
</name><etal/></person-group>. <article-title>Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>104</volume>(<issue>4</issue>):<fpage>448</fpage>–<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711410967">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kolovou</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Anagnostopoulou</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Cokkinos</surname>
<given-names>DV.</given-names>
</name>
</person-group> <article-title>Apolipoprotein E knockout models</article-title>. <source>Curr Pharm Des</source>. <year>2008</year>;<volume>14</volume>(<issue>4</issue>):<fpage>338</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711410967">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hingorani</surname>
<given-names>AD.</given-names>
</name>
</person-group> <article-title>Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000</article-title>. <source>Atherosclerosis</source>. <year>2001</year>;<volume>154</volume>(<issue>3</issue>):<fpage>521</fpage>–<lpage>527</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711410967">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
</person-group> <article-title>The endothelial nitric oxide synthase gene is associated with coronary artery disease: a meta-analysis</article-title>. <source>Cardiology</source>. <year>2010</year>;<volume>116</volume>(<issue>4</issue>):<fpage>271</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711410967">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnett</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Baird</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Barkley</surname>
<given-names>RA</given-names>
</name><etal/></person-group>. <article-title>American Heart Association Council on Epidemiology and Prevention; American Heart Association Stroke Council; Functional Genomics and Translational Biology Interdisciplinary Working Group. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>115</volume>(<issue>22</issue>):<fpage>2878</fpage>–<lpage>2901</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711410967">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gluba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Banach</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Rysz</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors</article-title>. <source>In Vivo</source>. <year>2009</year>;<volume>23</volume>(<issue>5</issue>):<fpage>797</fpage>–<lpage>812</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>